Filtered By:
Education: Grants
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 908 results found since Jan 2013.
Ischemic Stroke and Infection: A brief update on mechanisms and potential therapies
Biochem Pharmacol. 2021 Sep 17:114768. doi: 10.1016/j.bcp.2021.114768. Online ahead of print.ABSTRACTIschemic stroke triggers a multifaceted inflammatory response in the brain that contributes to secondary brain injury and infarct expansion. In parallel with brain inflammation, ischemic stroke also leads to post-stroke immunosuppression. Stroke-induced leukopenia then predisposes patients to opportunistic infections potentially leading to pneumonia or unrinary tract infections and a worsened stroke outcome. There is evidence that the hypothalamic-pituitary-adrenal axis plays an important role in the etiology of post-stroke...
Source: Biochemical Pharmacology - September 20, 2021 Category: Drugs & Pharmacology Authors: Drishti P Ghelani Hyun Ah Kim Shenpeng R Zhang Grant R Drummond Christopher G Sobey T Michael De Silva Source Type: research
Valve-in-valve transcatheter aortic valve implantation versus repeat surgical aortic valve replacement in patients with a failed aortic bioprosthesis
CONCLUSIONS: ViV TAVI was associated with lower in-hospital mortality but higher 30-day and 6-month all-cause readmission. However, there was no difference in risk of in-hospital stroke, post-procedure pacemaker implantation, MACE, and mortality during 30-day and 6-month readmission compared with repeat SAVR, suggesting that ViV TAVI can be performed safely in carefully selected patients.PMID:34521614 | DOI:10.4244/EIJ-D-21-00472
Source: EuroIntervention - September 15, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Monil Majmundar Rajkumar Doshi Ashish Kumar Douglas Johnston James Brockett Anmar Kanaa'N Joseph A Lahorra Lars G Svensson Amar Krishnaswamy Grant W Reed Rishi Puri Samir R Kapadia Ankur Kalra Source Type: research
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
EP44* Nimbus geometric clot extractor for tough clots - Real world clinical experience and clot composition
ConclusionsNimbus is effective in removing tough clots markedly rich in fibrin and platelets in challenging real world situations.ReferenceJens Fiehler. Failed thrombectomy in acute ischemic stroke: return of the stent? Stroke 2018;49:811–812. https://doi.org/10.1161/STROKEAHA.118.020541DisclosureThis series has emanated from research supported in part by a grant from Science Foundation Ireland (SFI) and the European Regional Development Fund (ERDF) under grant number 13/RC/2073_P2. It is the independent clinical practice of the authors. Cerenovus provided support for post hoc data collection and analysis.
Source: Journal of NeuroInterventional Surgery - August 24, 2021 Category: Neurosurgery Authors: Nordmeyer, H., Doyle, K., Gralla, J., Phung, T., Molina Gil, S., Belachew, N., Neuhaus, S., Douglas, A., Mordasini, P. Tags: Treatment Source Type: research
EP58 Procedural and functional outcomes for aspiration thrombectomy in acute ischemic stroke patients with differing clot dwell times: A subset analysis from the COMPLETE registry
ConclusionsPatients with longer clot dwell times were associated with more attempts and longer time to achieve reperfusion, more post-procedure complications, and lower likelihood of functional recovery.DisclosureOsama O. Zaidat: Grant/research support from Genentech, Medtronic Neurovascular, Stryker. Consultant for Codman, Medtronic Neurovascular, National Institutes of Health StrokeNet, Penumbra, Stryker. Honoraria from Codman, Medtronic Neurovascular, Penumbra, Stryker. Serves as an expert witness. Ownership interest in Galaxy Therapeutics, Inc. Johanna T. Fifi: Grant/research support: Microvention, Penumbra, Stryker. C...
Source: Journal of NeuroInterventional Surgery - August 24, 2021 Category: Neurosurgery Authors: Zaidat, O., Hassan, A., Abdul Kareem, S., Fifi, J. Tags: Treatment Source Type: research
NODDI highlights recovery mechanisms in white and gray matter in ischemic stroke following human stem cell treatment
CONCLUSIONS: NODDI compliments DTI metrics, enhances interpretation of tissue outcome in ischemic stroke following hMSC application, and may be useful in evaluating or predicting therapeutic response.PMID:34355818 | DOI:10.1002/mrm.28929
Source: Magnetic Resonance in Medicine - August 6, 2021 Category: Radiology Authors: F Andrew Bagdasarian Xuegang Yuan Jacob Athey Bruce A Bunnell Samuel C Grant Source Type: research
